Mature lymphoid B-cell proliferations with hairy cells represent heterogeneous entities where specific diagnosis is difficult but important since it impacts therapeutic management. The clinical cases of variant hairy cell leukemia reported herein illustrate the persistence of a clear interest in the use of splenectomy as a therapeutic alternative. Furthermore, ibrutinib appears to be a promising treatment in patients with relapsed/refractory disease.
Keywords: BRAFV600E; Ibrutinib; KDM6A; chronic B‐lymphoproliferative disorder; hairy cell leukemia; hairy cell leukemia variant.